Skip to main navigationSkip to main content
The University of Southampton
Southampton Health Technology Assessments Centre

Age-related macular degeneration

Click on the title for more information (where available).

Colquitt JL, Jones J, Tan SC, Takeda AL, Clegg AJ, Price A. Ranibizumab and pegaptanib for the treatment of age-related macular degeneration: a systematic review and economic evaluation. Health Technology Assessment 2008;12(16).  

Jones J, Raftery J, Tan SC, Clegg AJ, and Lotery A. Which price for sight? How good must Lucentis be relative to Avastin to be cost effective? HTAi Annual Meeting.  2007.
Raftery J, Clegg A, Jones J, Tan Seng C, Lotery A. Ranibizumab (lucentis) versus bevacizumab (avastin): modelling cost effectiveness. British Journal of Opthalmology 2007;91(9):1244-6.    

Takeda A, Colquitt J, Clegg AJ, Jones J. Pegaptanib and ranibizumab for neovascular age-related macular degeneration: a systematic review. Br J Ophthalmol 2007;91:1177-82.

Privacy Settings